A DNA chip, also referred to as a DNA microarray, is comparable to a computer chip. The key differentiating factor between the two is that a computer chip is imbedded with electronic circuitry, whereas a DNA gene chip is imbedded with DNA molecules. Or else it can be stated that DNA chip is a collection of DNA spots that are embedded on the solid surface. A DNA gene chip is about the size of a postage stamp. This technology has become very popular in the drug discovery and medical research sector as it significantly brings down research time. DNA microarrays play a vital role in helping medical researchers simultaneously measure the expression levels of several thousands of genes. The spiraling popularity of DNA chips has prompted many new players to enter the market and profit from their growing demand. In view of these aspects, the market for DNA gene chips is projected to show double-digit growth over the forecast period of this report. This technology is used to measure the expression levels of thousands of gene together at the same time.
Based on type, DNA gene chip market can be split into oDNA (oligonucleotide DNA) and cDNA (complementary DNA). The former is a dominant segment in the market, accounting for over 95% of the overall market share. The DNA gene chip market can also be classified by application as: comparative genomic hybridization, gene expression profiling, geneID, and others. The gene expression market emerges as the largest owing to its extensive applications in agriculture, clinical diagnostics, and other emerging sectors. This segment will likely demonstrate healthy growth over the forecast period as a result of substantial funding from governments and private players alike.
Request For Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4310
The report studies the DNA gene chip market based on geography by classifying it as: North America, Europe, Asia Pacific, and others. While North America was the dominant market in this sector until a few years ago, it is projected to reach maturity very soon and slip from its top position. On the other hand, aggressive growth in Asian economies such as China, Singapore, India, and South Korea will lead to a shift in the dynamics of the DNA microarray market. These markets are poised for massive growth as drug discovery and clinical trials intensify here.
Vital aspects of value of the DNA gene chip market include a strong supply chain, world-class logistical connectivity, cutting-edge scientific infrastructure, and the availability of skilled manpower. Singapore boasts leadership on all these fronts, making it a hub for the DNA gene chip market. Most of the companies are focing on setting up of facilities in this region due to strong intellectual property laws, logistics connectivity and supply chain.
Growth in personalized medicines, rising prevalence of cancer, technology advancements and large scale initiatives by the organization are some of the major drivers of this market. According to the World Health Organization (WHO) worldwide 8.2 million people died of cancer in 2012. In 2013, American Cancer Society (ACS) published that, around 300,000 men and 276,000 women died due to cancer in 2012 in the U.S. Moreover, California Journal of Clinical Cancer (CJCC) stated that, one in the every six U.S. men have received diagnosis test for prostate cancer at some point in their lives. Hence, such high prevalence of diseased condition would raise the growth of the market to a higher end.
Some of the majors players of the DNA chip market include Affymetrix, Inc., Agilent Technologies, Biomérieux Sa, Biometrix Technology Inc, Capitalbio Corporation, Bioneer Corporation, Eurofins Mwg Operon, Illumina Inc., Greiner Bio-One, Lc Sciences, Life Technologies Corporation, Microarrays Inc, Macrogen Inc, Sequenom Inc, Scienion Ag, Sigma-Aldrich, Savyon Diagnostics Ltd, Roche Nimblegen Inc, Wafergen Biosystems Inc and others.
No comments:
Post a Comment